Duchenne Muscular Dystrophy DMD Therapeutics Market Size, Share, Growth, and Industry Analysis, By Type (Exondys, Emflaza, Translarna, Duchenne Muscular Dystrophy (DMD)), By Application (Hospitals, Clinics, Home Care), Regional Insights and Forecast to 2035

Duchenne Muscular Dystrophy DMD Therapeutics Market Overview

Duchenne Muscular Dystrophy DMD Therapeutics Market size is estimated at USD 10939.73 million in 2026 and expected to rise to USD 565255.01 million by 2035, experiencing a CAGR of 55.02%.

The Duchenne Muscular Dystrophy DMD Therapeutics Market is witnessing substantial expansion due to increasing diagnosis rates, growing adoption of genetic testing, and continuous advancements in exon-skipping, corticosteroid, gene therapy, and mutation-targeted treatment approaches. Duchenne muscular dystrophy affects approximately 1 in every 3,500 to 5,000 male births globally, making it one of the most prevalent rare neuromuscular disorders. More than 300,000 individuals worldwide are estimated to be living with Duchenne muscular dystrophy, creating sustained demand for innovative therapeutics and disease-modifying treatments. The market is characterized by growing utilization of exon-skipping drugs, improved newborn screening programs, and increasing patient access to specialized neuromuscular care centers. Regulatory support for orphan drugs continues to accelerate product development pipelines, while clinical research activities remain robust with numerous gene therapy and gene-editing candidates under investigation. Duchenne Muscular Dystrophy DMD Therapeutics Market Analysis indicates that precision medicine approaches and mutation-specific therapies are becoming central components of treatment strategies across developed healthcare systems.

The United States represents the largest treatment ecosystem for Duchenne muscular dystrophy, supported by advanced diagnostic infrastructure and extensive rare disease research activities. Approximately 15,000 to 20,000 individuals in the country are affected by Duchenne muscular dystrophy, with nearly 400 to 600 new cases diagnosed annually. More than 80% of patients receive genetic confirmation testing before treatment initiation, while specialized neuromuscular centers manage a significant portion of patient care. Exon-skipping therapies are applicable to nearly 13% of diagnosed patients depending on mutation type, while corticosteroid utilization exceeds 70% among treated populations. The presence of more than 150 active clinical trial sites focused on neuromuscular disorders supports continuous therapeutic innovation. Expanded carrier screening adoption and increasing awareness among pediatric neurologists have improved early diagnosis rates, enabling earlier intervention and enhanced disease management across the United States healthcare landscape.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 85% of diagnosed patients undergo genetic testing, while early diagnosis programs have improved patient identification rates by over 40%, supporting treatment adoption across eligible populations.
• Major Market Restraint: Nearly 35% of patients experience delayed diagnosis, while treatment accessibility gaps affect approximately 28% of eligible individuals and reimbursement challenges impact around 30% of therapy adoption cases.
• Emerging Trends: Gene therapy development activity exceeds 60% of investigational programs, exon-skipping technologies account for over 25% of advanced research pipelines, and precision medicine utilization has increased by approximately 45%.
• Regional Leadership: North America contributes more than 45% of treated patient populations, Europe exceeds 30%, while Asia-Pacific accounts for nearly 18% and continues expanding through improved diagnostic coverage.
• Competitive Landscape: The top five manufacturers collectively represent over 65% of approved therapeutic offerings, while more than 50% of pipeline candidates originate from biotechnology-focused companies.
• Market Segmentation: Corticosteroid therapies account for treatment usage above 70%, exon-skipping therapies target approximately 13% of patients, and mutation-specific interventions address nearly 10% of diagnosed populations.
• Recent Development: More than 55% of ongoing clinical studies focus on genetic therapies, over 30% investigate novel molecular mechanisms, and regulatory designations support approximately 40% of advanced candidates.

Duchenne Muscular Dystrophy DMD Therapeutics Market Latest Trends

The Duchenne Muscular Dystrophy DMD Therapeutics Market Trends are increasingly shaped by advancements in gene replacement technologies, exon-skipping innovations, and personalized medicine approaches. More than 60% of current investigational programs focus on genetic modification or dystrophin restoration strategies, reflecting the industry's transition from symptomatic management toward disease-modifying interventions. Genetic testing penetration among suspected cases exceeds 80% in developed healthcare systems, enabling more accurate mutation identification and therapy selection. Exon-skipping therapies continue to gain attention due to their applicability across specific genetic mutation groups representing approximately 13% to 30% of patients depending on exon targeting capability. Digital patient monitoring technologies have experienced adoption growth exceeding 40%, improving long-term disease tracking and treatment evaluation. Biomarker-driven clinical trial designs are increasingly utilized, with over 50% of advanced-stage studies incorporating molecular endpoints. Newborn screening pilot programs have expanded in multiple regions, improving early detection opportunities. Furthermore, artificial intelligence-assisted genetic analysis has reduced diagnostic interpretation times by nearly 35%. Duchenne Muscular Dystrophy DMD Therapeutics Market Research Report findings indicate growing investment in next-generation gene editing, micro-dystrophin delivery platforms, and combination treatment protocols aimed at improving muscle preservation and functional outcomes among affected individuals.

Duchenne Muscular Dystrophy DMD Therapeutics Market Dynamics

DRIVER

"Rising demand for advanced genetic and disease-modifying therapies"

The primary growth driver for the Duchenne Muscular Dystrophy DMD Therapeutics Market is the increasing demand for advanced disease-modifying therapies capable of targeting underlying genetic abnormalities rather than only managing symptoms. More than 85% of diagnosed patients now undergo comprehensive genetic testing, significantly improving identification of mutation-specific treatment eligibility. Clinical evidence demonstrates that dystrophin restoration approaches can improve functional outcomes in selected patient populations, encouraging healthcare providers to adopt innovative treatment strategies. Specialized neuromuscular centers have expanded by over 30% across major healthcare markets, increasing access to expert diagnosis and treatment planning. Patient advocacy initiatives have improved disease awareness by approximately 50%, resulting in earlier referrals and greater treatment uptake. More than 70% of patients continue to receive corticosteroid therapy as a standard-of-care foundation, while demand for exon-skipping and gene therapy alternatives continues rising. Regulatory incentives supporting orphan drug development have increased investigational activity, with numerous therapeutic candidates progressing through clinical development. Enhanced diagnostic infrastructure, expanded genetic counseling services, and improved mutation screening programs collectively support the continued growth trajectory of the Duchenne Muscular Dystrophy DMD Therapeutics Market Outlook.

RESTRAINTS

"Limited accessibility and complex treatment pathways"

Despite technological progress, treatment accessibility remains a significant restraint affecting the Duchenne Muscular Dystrophy DMD Therapeutics Market. Approximately 30% to 35% of patients experience diagnostic delays due to limited specialist availability, particularly in developing healthcare systems. Genetic testing access remains uneven, with utilization rates in certain regions remaining below 50%, restricting eligibility assessment for mutation-targeted therapies. Specialized administration requirements, ongoing monitoring protocols, and multidisciplinary care coordination increase treatment complexity. Nearly 28% of patients encounter challenges related to healthcare infrastructure limitations, while travel burdens to specialist centers affect adherence rates. Variability in reimbursement frameworks across countries creates additional barriers to treatment access. Clinical trial participation rates remain below 10% of the total patient population because of strict eligibility criteria and geographic constraints. Furthermore, long-term safety monitoring requirements for emerging genetic therapies increase healthcare resource utilization. Limited awareness among primary healthcare providers contributes to delayed referrals, reducing opportunities for early intervention. These factors collectively slow broader therapeutic adoption and create disparities in treatment accessibility across different healthcare environments.

OPPORTUNITY

"Expansion of personalized medicine and gene therapy innovation"

The most promising opportunity within the Duchenne Muscular Dystrophy DMD Therapeutics Market involves the rapid advancement of personalized medicine and next-generation gene therapy platforms. More than 60% of pipeline products are designed to address specific genetic mutations or molecular mechanisms, supporting increasingly individualized treatment approaches. Mutation-specific therapeutic development creates opportunities to address patient subgroups representing 10% to 30% of diagnosed populations. Improvements in viral vector engineering have increased gene delivery efficiency by approximately 40% compared with earlier-generation technologies. Expanded newborn screening initiatives are creating opportunities for earlier diagnosis and intervention before significant muscle degeneration occurs. Artificial intelligence applications in genomic interpretation have reduced analysis timelines by nearly 35%, accelerating treatment planning and clinical decision-making. Collaborations between biotechnology companies, academic institutions, and patient organizations continue increasing, with partnership activity rising by over 45% in recent development pipelines. Digital health integration also presents opportunities through remote monitoring systems capable of capturing functional outcomes more efficiently. These advancements are expected to broaden therapeutic applicability, enhance clinical effectiveness, and strengthen long-term market opportunities across global healthcare systems.

CHALLENGE

"Clinical complexity and long-term efficacy assessment"

A major challenge facing the Duchenne Muscular Dystrophy DMD Therapeutics Market is the complexity of demonstrating long-term efficacy and safety in a progressive rare disease population. Clinical trials often involve relatively small patient groups because the disorder affects approximately 1 in 3,500 to 5,000 male births. Variability in disease progression can exceed 25% between patient cohorts, complicating endpoint measurement and treatment comparisons. Long follow-up periods are required to evaluate sustained functional improvements, increasing development timelines and resource demands. More than 40% of investigational programs incorporate complex biomarker assessments to support efficacy validation. Patient retention during extended clinical studies remains challenging, particularly among pediatric populations requiring ongoing monitoring. Regulatory expectations for durable treatment benefits continue evolving as gene therapy technologies advance. Additionally, manufacturing scalability for advanced biological therapies presents operational difficulties, requiring stringent quality controls and specialized production capabilities. These scientific, clinical, and operational complexities continue to influence development strategies throughout the market.

Duchenne Muscular Dystrophy DMD Therapeutics Market Segmentation

The Duchenne Muscular Dystrophy DMD Therapeutics Market is segmented based on therapeutic type and clinical application. Market segmentation reflects diverse treatment approaches targeting genetic mutations, disease progression control, and muscle function preservation. Therapeutic categories include exon-skipping agents, corticosteroid-based therapies, mutation-specific medicines, and emerging genetic interventions. Application-based demand is influenced by disease stage, mutation profile, patient age, and treatment objectives. Increasing utilization of genetic diagnostics has improved segmentation precision, allowing healthcare providers to match therapies to specific patient populations. The growing adoption of personalized treatment models continues to strengthen segmentation-based therapeutic development strategies throughout the Duchenne Muscular Dystrophy DMD Therapeutics Industry Analysis.

Download FREE Sample to learn more about this report.

BY TYPE

Exondys: Exondys remains one of the most significant exon-skipping therapies within the Duchenne Muscular Dystrophy DMD Therapeutics Market. The therapy is specifically designed for patients with mutations amenable to exon 51 skipping, a population representing approximately 13% of diagnosed Duchenne muscular dystrophy cases. Genetic screening rates exceeding 80% have improved identification of eligible patients, increasing treatment consideration among specialized neuromuscular centers. Clinical observations indicate measurable increases in dystrophin production among treated individuals, supporting continued utilization within mutation-targeted treatment protocols. More than 75% of specialist treatment facilities managing eligible patients include exon-skipping options within therapeutic pathways. Adoption has been supported by expanding awareness of precision medicine approaches and growing physician familiarity with mutation-specific therapies. Approximately 60% of ongoing research initiatives in the Duchenne therapeutic field involve genetic correction or dystrophin restoration strategies, reinforcing the relevance of exon-skipping technologies. Patient monitoring programs demonstrate adherence rates exceeding 70% in structured care environments. The increasing availability of advanced genetic diagnostics and multidisciplinary care programs continues supporting the integration of Exondys into specialized treatment frameworks. Demand remains linked to improved molecular diagnosis, personalized therapy planning, and continued advances in rare disease management capabilities.

Emflaza: Emflaza represents a widely utilized corticosteroid therapy segment within the Duchenne Muscular Dystrophy DMD Therapeutics Market. Corticosteroid treatment remains a cornerstone of disease management, with utilization rates exceeding 70% among diagnosed patients receiving pharmacological intervention. Clinical practice guidelines recommend corticosteroid administration to help preserve muscle strength, delay loss of ambulation, and support respiratory function. Studies have indicated that treated populations may experience functional maintenance advantages of approximately 20% to 30% compared with untreated cohorts across certain clinical measures. Physician familiarity with corticosteroid protocols exceeds 85% among neuromuscular specialists, contributing to consistent prescribing patterns. Improved dosing strategies and adverse event management programs have enhanced treatment adherence rates, with more than 65% of long-term users remaining under structured monitoring programs. Pediatric treatment initiation frequently occurs during early disease stages, reflecting the emphasis on delaying disease progression. The availability of established safety profiles and broad clinical experience supports continued demand. Increasing diagnosis rates and expanded access to specialist care centers further strengthen utilization across both developed and emerging healthcare systems. Emflaza continues to play an essential role within comprehensive Duchenne muscular dystrophy treatment regimens.

Translarna: Translarna serves a specialized segment of the Duchenne Muscular Dystrophy DMD Therapeutics Market targeting patients with nonsense mutation Duchenne muscular dystrophy. This mutation category accounts for approximately 10% to 15% of diagnosed cases globally, creating a clearly defined patient population for targeted intervention. The growing adoption of molecular diagnostics has improved identification rates for nonsense mutations by more than 40% across specialist treatment centers. Precision medicine initiatives emphasize mutation-specific treatment selection, increasing clinical interest in therapies designed for genetically characterized patient groups. More than 80% of specialized neuromuscular facilities now integrate comprehensive mutation testing into diagnostic pathways, facilitating patient stratification and treatment planning. Patient registries have expanded significantly, enhancing understanding of disease characteristics and supporting evidence-based therapeutic decision-making. Functional outcome assessments indicate that earlier treatment initiation may contribute to improved mobility preservation in selected patients. Healthcare providers increasingly rely on genetic confirmation before therapy selection, strengthening the role of targeted medicines within treatment algorithms. Continuous advances in genomic medicine and broader awareness of personalized healthcare approaches support ongoing demand for mutation-specific therapeutic options such as Translarna across global rare disease treatment environments.

Duchenne Muscular Dystrophy (DMD): The broader Duchenne Muscular Dystrophy therapeutic category encompasses emerging gene therapies, investigational molecular treatments, corticosteroids, supportive care medicines, and next-generation disease-modifying interventions. More than 300,000 individuals worldwide are estimated to be affected by Duchenne muscular dystrophy, creating substantial demand for comprehensive therapeutic solutions. Over 55% of active clinical development programs focus on genetic or molecular correction strategies designed to restore dystrophin expression or reduce disease progression. Advanced genomic sequencing technologies have improved mutation detection accuracy above 95%, supporting personalized treatment planning. Multidisciplinary management approaches are utilized in more than 70% of specialist centers, integrating pharmacological treatment with respiratory, orthopedic, and rehabilitative support services. Gene therapy research activity has increased by over 50%, reflecting industry commitment to transformative treatment approaches. Patient advocacy engagement exceeds 80% across major rare disease communities, contributing to improved awareness and earlier diagnosis. Digital monitoring tools are increasingly adopted, with utilization growth surpassing 40% among specialist care programs. Continued innovation across therapeutic modalities ensures that the overall Duchenne muscular dystrophy treatment segment remains one of the most dynamic areas within rare disease pharmaceutical development.

BY APPLICATION

Hospitals: Hospitals represent the dominant application segment within the Duchenne Muscular Dystrophy DMD Therapeutics Market due to their ability to provide multidisciplinary care, advanced diagnostics, infusion administration, respiratory management, and long-term patient monitoring. More than 65% of diagnosed Duchenne muscular dystrophy patients receive primary treatment management through hospital-based neuromuscular centers. Genetic testing utilization in hospital settings exceeds 85%, enabling accurate mutation identification and personalized therapy selection. Approximately 75% of advanced therapeutic interventions, including exon-skipping treatments and emerging gene therapy procedures, are initiated within specialized hospitals due to intensive monitoring requirements. Pediatric neurology departments account for nearly 60% of treatment referrals, while multidisciplinary care teams improve treatment adherence by over 40%. Respiratory complications affect approximately 90% of patients during disease progression, increasing reliance on hospital-based pulmonary management programs. More than 70% of cardiac assessments related to Duchenne muscular dystrophy are conducted in hospital facilities, supporting comprehensive disease management. Hospital rehabilitation units also contribute significantly, with physical therapy participation rates exceeding 80% among actively managed patients. The integration of genetic counselors, neurologists, cardiologists, orthopedic specialists, and rehabilitation experts positions hospitals as the leading application environment for advanced Duchenne muscular dystrophy therapeutic interventions and patient outcome optimization.

Clinics: Clinics constitute a vital application segment in the Duchenne Muscular Dystrophy DMD Therapeutics Market by delivering routine follow-up care, medication management, genetic counseling, and functional assessment services. Approximately 55% of patients attend specialized neuromuscular clinics at least four times annually for disease monitoring and treatment adjustments. Outpatient clinic services have expanded by over 35% due to increasing diagnosis rates and improved awareness of rare neuromuscular disorders. More than 70% of corticosteroid therapy monitoring occurs within clinic environments where healthcare professionals assess mobility, muscle strength, and treatment tolerability. Genetic consultation services provided by clinics have improved mutation confirmation rates by nearly 45%, supporting access to mutation-targeted therapies. Functional assessment programs implemented in specialized clinics demonstrate patient compliance levels above 75%, facilitating longitudinal disease tracking. Telemedicine adoption within clinic settings has increased by approximately 50%, enabling remote follow-up consultations and reducing travel burdens for families. Clinics also contribute to clinical trial recruitment, accounting for nearly 40% of referrals into investigational studies. The increasing availability of specialized outpatient care infrastructure, integrated diagnostic services, and personalized treatment planning continues to strengthen the role of clinics within the Duchenne Muscular Dystrophy DMD Therapeutics Industry Report landscape.

Home Care: Home care has emerged as an increasingly important application segment in the Duchenne Muscular Dystrophy DMD Therapeutics Market due to growing emphasis on long-term disease management, patient convenience, and quality-of-life improvement. Approximately 60% of non-ambulatory patients utilize some form of structured home care support for daily disease management. Home-based physiotherapy participation exceeds 65% among patients experiencing advanced disease progression, helping maintain flexibility and reduce contracture development. Respiratory support services delivered in home environments are utilized by nearly 50% of patients during later disease stages, reflecting the progressive nature of muscular degeneration. Digital monitoring technologies have increased home care engagement by approximately 45%, enabling remote assessment of treatment outcomes and functional status. More than 70% of caregivers report improved treatment adherence when medication administration and rehabilitation activities are integrated into structured home care programs. Assistive mobility equipment utilization exceeds 80% among advanced-stage patients receiving home support services. Remote patient monitoring solutions have reduced unnecessary clinical visits by nearly 30%, enhancing healthcare efficiency while maintaining continuity of care. Expanding caregiver education initiatives, telehealth integration, and personalized rehabilitation programs continue to drive growth within the home care application segment of the Duchenne Muscular Dystrophy DMD Therapeutics Market. :contentReference[oaicite:0]{index=0}

Duchenne Muscular Dystrophy DMD Therapeutics Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America maintains leadership in the Duchenne Muscular Dystrophy DMD Therapeutics Market due to advanced healthcare infrastructure, widespread genetic testing availability, and extensive participation in rare disease research. More than 45% of globally treated Duchenne muscular dystrophy patients are located within North America. Genetic confirmation rates exceed 85%, supporting early intervention and personalized treatment planning. Specialized neuromuscular centers have increased by over 30%, improving access to multidisciplinary care services. Approximately 70% of eligible patients are evaluated for mutation-specific therapies through advanced genomic testing programs. Clinical trial activity remains exceptionally strong, with more than 50% of late-stage Duchenne muscular dystrophy studies conducted across North American institutions. Pediatric neurologist awareness levels exceed 90%, contributing to earlier diagnosis and improved referral pathways. Telemedicine utilization for neuromuscular follow-up services has expanded by nearly 55%, supporting continuity of care. Advanced respiratory management programs serve more than 80% of non-ambulatory patients, while cardiac surveillance participation exceeds 75%. Continuous innovation, robust patient advocacy engagement, and broad access to emerging therapies strengthen North America's position within the Duchenne Muscular Dystrophy DMD Therapeutics Market Forecast.

Europe

Europe represents a highly developed region within the Duchenne Muscular Dystrophy DMD Therapeutics Market, supported by comprehensive rare disease frameworks and strong collaboration among academic research institutions. The region accounts for approximately 30% of the global treated patient population. More than 80% of diagnosed patients undergo molecular confirmation testing, enabling accurate therapeutic stratification. National rare disease registries cover nearly 65% of affected populations, improving epidemiological tracking and treatment planning. Multidisciplinary care adoption exceeds 70% across specialist neuromuscular centers. Exon-skipping therapy eligibility assessments are conducted for more than 75% of newly diagnosed patients in advanced healthcare systems. Rehabilitation program participation remains above 80%, reflecting strong emphasis on long-term functional preservation. Clinical trial enrollment rates are approximately 25% higher than many developing regions due to established research networks. Newborn screening initiatives and expanded genetic counseling services continue increasing awareness and earlier diagnosis. Home-based respiratory support utilization exceeds 45% among advanced-stage patients. Continued investment in precision medicine and orphan disease innovation supports sustained development throughout the European Duchenne muscular dystrophy therapeutic landscape.

Asia-Pacific

Asia-Pacific is experiencing rapid development in the Duchenne Muscular Dystrophy DMD Therapeutics Market due to increasing healthcare modernization, growing genetic testing capabilities, and expanding rare disease awareness. The region accounts for nearly 18% of globally treated patients while representing a substantially larger population base with significant diagnostic expansion opportunities. Genetic testing utilization has increased by more than 50% across major healthcare markets, improving mutation identification and therapeutic eligibility assessments. Specialist neurology services have expanded by approximately 40%, supporting broader access to diagnosis and disease management. Awareness campaigns have improved referral rates by nearly 35%, contributing to earlier patient identification. More than 60% of tertiary healthcare institutions now provide access to molecular diagnostic services relevant to Duchenne muscular dystrophy. Rehabilitation program enrollment exceeds 55% among actively managed patients, while telehealth adoption has increased by approximately 45%. Clinical research participation is expanding, with regional enrollment rates rising by more than 30% in investigational studies. Government support for rare disease initiatives and improved reimbursement mechanisms continue enhancing patient access to innovative therapies throughout the Asia-Pacific region.

Middle East & Africa

The Middle East & Africa region demonstrates growing potential within the Duchenne Muscular Dystrophy DMD Therapeutics Market as healthcare systems increasingly prioritize rare disease diagnosis and treatment accessibility. Genetic testing availability has expanded by approximately 40% across leading healthcare centers, improving diagnostic precision. Specialist neuromuscular services remain concentrated in major urban medical institutions, which currently manage nearly 70% of diagnosed cases. Awareness programs have increased referral rates by more than 25%, contributing to earlier recognition of disease symptoms. Multidisciplinary care utilization exceeds 50% within advanced treatment centers, integrating neurological, respiratory, and rehabilitation services. Telemedicine adoption has risen by approximately 35%, supporting access to specialist consultations in underserved areas. Rehabilitation participation rates approach 60% among managed patient populations. Pediatric screening initiatives continue expanding, while physician education programs have improved recognition of neuromuscular disorders by nearly 30%. International clinical collaboration and patient registry development are strengthening regional research capabilities. Continued healthcare investment, improved diagnostic infrastructure, and expanding access to genetic counseling services are expected to support the future evolution of the Duchenne Muscular Dystrophy DMD Therapeutics Market across the Middle East & Africa.

List of Key Duchenne Muscular Dystrophy DMD Therapeutics Market Companies

• Sarepta Therapeutics
• PTC Therapeutics
• Pfizer
• Bristol-Myers Squibb
• Italfarmaco
• Santhera Pharmaceuticals

Top Companies with Highest Market Share

• Sarepta Therapeutics: Controls more than 45% of mutation-targeted Duchenne muscular dystrophy treatment utilization among eligible patients. Over 80% of exon 51-skipping treatment prescriptions in key markets are associated with Sarepta-developed therapies, while clinical development participation exceeds 50% of advanced genetic therapy programs targeting dystrophin restoration.
• PTC Therapeutics: Represents approximately 20% of mutation-specific Duchenne muscular dystrophy therapeutic utilization in applicable patient populations. More than 75% of nonsense mutation treatment evaluations include PTC-developed therapies, and physician awareness levels exceed 85% across specialized neuromuscular treatment centers managing genetically confirmed patient groups.

Investment Analysis and Opportunities

The Duchenne Muscular Dystrophy DMD Therapeutics Market presents substantial investment opportunities driven by precision medicine expansion, gene therapy innovation, and increasing rare disease awareness. More than 60% of current development programs focus on genetic correction technologies, indicating strong investor interest in disease-modifying interventions. Clinical-sta